Evidence map›Paper›PMID 32754270›Full record

Trial reportTheranostics2020

Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids.

David de Gonzalo-Calvo, Pablo Martínez-Camblor, Christian Bär, Kevin Duarte, Nicolas Girerd, Bengt Fellström, Roland E Schmieder, Alan G Jardine, Ziad A Massy, Hallvard Holdaas and 3 more

Abstract readClinical Trial, Phase IClinical Trial, Phase II
In one paragraph

Trial report in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients.Translational research : the journal of laboratory and clinical medicine · 2021
    Trial
  5. Article
  6. MicroRNAs in neurodegenerative diseases: from molecular mechanisms to clinical biomarkers, detection methods and therapeutic strategies-advances and challenges.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Noncoding RNome as Enabling Biomarkers for Precision Health.International journal of molecular sciences · 2022
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

David de Gonzalo-CalvoInstitute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany.
Pablo Martínez-CamblorGeisel School of Medicine, Dartmouth College, Hanover, NH, USA.
Christian BärInstitute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany.
Kevin DuarteUniversité de Lorraine, Inserm, Centre d'Investigations cliniques-plurithématique 1433, Inserm U1116; CHRU Nancy; F-CRIN INI-CRCT network, Nancy, France.
Nicolas GirerdUniversité de Lorraine, Inserm, Centre d'Investigations cliniques-plurithématique 1433, Inserm U1116; CHRU Nancy; F-CRIN INI-CRCT network, Nancy, France.
Bengt FellströmDepartment of Medical Sciences, Renal Unit, Uppsala University Hospital, Uppsala, Sweden.
Roland E SchmiederDepartment of Nephrology and Hypertension, University Hospital, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Germany.
Alan G JardineInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Ziad A MassyDivision of Nephrology, Ambroise Paré University Medical Center, APHP, Boulogne Billancourt, F-92100 Paris, France.
Hallvard HoldaasDepartment of Transplantation Medicine, Rikshospitalet, Oslo University Hospital, Oslo, Norway.
Patrick RossignolUniversité de Lorraine, Inserm, Centre d'Investigations cliniques-plurithématique 1433, Inserm U1116; CHRU Nancy; F-CRIN INI-CRCT network, Nancy, France.
Faiez ZannadUniversité de Lorraine, Inserm, Centre d'Investigations cliniques-plurithématique 1433, Inserm U1116; CHRU Nancy; F-CRIN INI-CRCT network, Nancy, France.
Thomas ThumInstitute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAged, 80 and overBiomarkersCardiovascular DiseasesCase-Control StudiesFemaleHumansKidney Failure, ChronicMachine LearningMaleMicroRNAsMiddle AgedRegression AnalysisRenal DialysisReverse Transcriptase Polymerase Chain ReactionSequence Analysis, RNABiomarkersMicroRNAsMIRN186 microRNA, humanMIRN632 microRNA, humanBiomarkerCardiovascular riskHemodialysisKidney diseaseMachine learningmicroRNA.

Identifiers

PMID32754270
PMCPMC7392028

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.